These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989 [TBL] [Abstract][Full Text] [Related]
4. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525 [TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Ahn IE; Davids MS Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398 [TBL] [Abstract][Full Text] [Related]
9. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245 [TBL] [Abstract][Full Text] [Related]
10. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232 [TBL] [Abstract][Full Text] [Related]
13. Pathways and mechanisms of venetoclax resistance. Bose P; Gandhi V; Konopleva M Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780 [TBL] [Abstract][Full Text] [Related]
15. Venetoclax for the treatment of multiple myeloma. Vaxman I; Sidiqi MH; Gertz M Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277 [No Abstract] [Full Text] [Related]
16. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442 [TBL] [Abstract][Full Text] [Related]
17. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Crombie J; Davids MS Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339 [TBL] [Abstract][Full Text] [Related]
18. Development of venetoclax for therapy of lymphoid malignancies. Zhu H; Almasan A Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288 [TBL] [Abstract][Full Text] [Related]
20. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. Roberts AW; Huang D Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]